Analysis of Free Drug Content in Antibody-Drug Conjugate Using 2D-LC/Q-TOF

Importance of Topic

Antibody–drug conjugates (ADCs) represent a cutting-edge class of biotherapeutics that deliver potent cytotoxic agents directly to tumor cells while sparing healthy tissue. Accurate measurement of free (unconjugated) drug in ADC formulations is essential to ensure product safety, efficacy, and regulatory compliance. Elevated levels of free drug can arise from incomplete conjugation or degradation, potentially increasing toxicity and reducing therapeutic performance.

Study Objectives and Overview

This application note demonstrates a streamlined two-dimensional liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (2D-LC/Q-TOF) workflow to quantify free drug content in ADC samples. The approach integrates size-exclusion chromatography (SEC) in the first dimension to separate high-molecular-weight ADCs from small molecules, followed by reversed-phase (RP) chromatography in the second dimension to resolve and identify the drug and linker-drug species without offline sample cleanup.

Methodology

• 1D SEC separates intact ADCs from low-molecular-weight species using a neutral ammonium acetate buffer with 40 % acetonitrile to improve elution of hydrophobic components.
• Heart-cutting transfers three continuous SEC fractions containing free drug peaks into the 2D RP column via multi-inject loops for high-resolution separation.
• 2D RP employs a C18 column and gradient elution to resolve the native drug (DM1) and linker-drug (SMCC-DM1) diastereomers.

Instrumentation Used

• Agilent 1290 Infinity II Bio 2D-LC system with high-speed pumps, multisampler, and valve drives
• Agilent AdvanceBio SEC and Poroshell EC-C18 columns
• Agilent 6545XT AdvanceBio LC/Q-TOF with Dual Jet Stream ESI source
• Agilent MassHunter Acquisition and Qualitative Analysis software

Main Results and Discussion

SEC scouting showed that 40 % acetonitrile in the mobile phase achieved sharp elution of the free drug standard. Heart-cut SEC separated ADC from small molecules, but DM1 and SMCC-DM1 coeluted as a broad peak requiring multi-cut sampling. Subsequent RP separation resolved DM1 ([M+H]+ m/z 738.2839, Δ2.3 ppm) and the SMCC-DM1 diastereomeric pair ([M+H]+ m/z 1,072.3985, Δ0.18 ppm). High-resolution MS confirmed molecular identities and detected characteristic adducts and fragment ions.

Benefits and Practical Applications

• Online protein removal protects RP columns from fouling and reduces manual sample prep
• Automated heart-cutting multiplexes fractions into a single RP run, shortening total analysis to 17 minutes
• High mass accuracy enables confident identification of free drug species in complex ADC matrices

Future Trends and Opportunities

Advances may include integration with higher-throughput fractionation, addition of ion mobility for isomer resolution, application to diverse linker chemistries, and AI-driven method optimization. Further miniaturization and coupling with orthogonal detectors could broaden utility in ADC development and quality control.

Conclusion

The 2D-LC/Q-TOF method effectively quantifies free drug content in ADCs by combining SEC-based protein removal with high-resolution RP separation and MS detection. This streamlined, fully automated workflow improves sensitivity, reduces analysis time, and safeguards column integrity, supporting robust ADC characterization.

References

1. Li Y. et al. Limiting Degradation of Reactive Antibody Drug Conjugate Intermediates in HPLC Method Development. J. Pharm. Biomed. Anal. 2014;92:114–118.
2. Hurwitz E. et al. The Covalent Binding of Daunomycin and Adriamycin to Antibodies With Retention of Both Drug And Antibody Activities. Cancer Res. 1975;35:1175–1181.
3. Chari R. V. et al. Enhancement of the Selectivity and Antitumor Efficacy of a CC-1065 Analogue Through Immunoconjugate Formation. Cancer Res. 1995;55:4079–4084.
4. Wong D. Characterization of Antibody-Drug Conjugates Using 2D-LC and Native MS. Agilent Technologies Application Note 5994-4328EN, 2021.
5. Stoll D. R. Recent Advances in 2D-LC for Bioanalysis. Bioanalysis 2015;7(24):3125–3142.
6. Singh R. et al. A New Triglycyl Peptide Linker for Antibody–Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells. Mol. Cancer Ther. 2016;15(6):1311–1320.